| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/24/2007 | WO2007057093A1 3, 6-dihydro-2-oxo-6h-(1,3,4)thiadiazine derivatives |
| 05/24/2007 | WO2007057092A1 Substituted 5-phenyl-3,6-dihydro-2-oxo-6h-[1,3,4]thiadiazines |
| 05/24/2007 | WO2007057090A1 A combination comprising squalene, a phospholipid and an omega 3 fatty acid for the treatment of cancer |
| 05/24/2007 | WO2007056941A1 The use of isothiocyanates compounds in treating prostatic diseases and skin cancer |
| 05/24/2007 | WO2007056867A1 Modified pore-forming protein toxins and use thereof |
| 05/24/2007 | WO2007056858A1 Anti-alpha2 integrin antibodies and their uses |
| 05/24/2007 | WO2007056854A1 Method of expanding double negative t cells |
| 05/24/2007 | WO2007056852A1 Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| 05/24/2007 | WO2007056847A1 Stabilizing formulations for recombinant viruses |
| 05/24/2007 | WO2007056812A1 A molecule and chimeric molecules thereof |
| 05/24/2007 | WO2007044449A3 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 05/24/2007 | WO2007040650A3 Apoptosis promoters |
| 05/24/2007 | WO2007037133A9 Method for evaluation of compound capable of acting on plk3 |
| 05/24/2007 | WO2007022044A3 Combination of organic compounds |
| 05/24/2007 | WO2007014743A3 Cd33-specific single-chain immunotoxin and method of use |
| 05/24/2007 | WO2007008463A3 Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| 05/24/2007 | WO2006071960A3 Compositions and methods of treating cell proliferation disorders |
| 05/24/2007 | WO2000009653A3 Method of inhibiting cathepsin k |
| 05/24/2007 | US20070117856 Indazole derivatives |
| 05/24/2007 | US20070117850 substituted or unsubstituted 2-pyridyl moiety and a pyrozole ring substituted at 4 position with pyridine ring; inhibits the TGF-beta signaling pathway; anticancer, antifibrotic, antitumor, and antiproliferative agents |
| 05/24/2007 | US20070117842 Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same |
| 05/24/2007 | US20070117773 Telomerase-inhibiting ENA oligonucleotide |
| 05/24/2007 | US20070117758 Treating treating angiogenic disease, e.g., cancer, by administering therapeutically effective amount of compounds of the invention, for example, {(3R, 4S, 5S, 6R)-5-Methoxy-4-[(2R, 3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid methyl ester |
| 05/24/2007 | US20070117754 Nectin polypeptides, polynucleotides, methods of making and use thereof |
| 05/24/2007 | US20070117180 Enzyme producing plasma protein fragment having inhibitory activity to metastasis and growth of cancer and plasma protein fragment produced by fragmentation by said enzyme |
| 05/24/2007 | US20070117166 Use of ULIP proteins in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes |
| 05/24/2007 | US20070117165 Detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells |
| 05/24/2007 | US20070117163 Anti-aurora-a monoclonal antibody, method for obtaining same and uses thereof for diagnosing and treating cancers |
| 05/24/2007 | US20070117142 Regulation of novel human asparagine-hydroxylases |
| 05/24/2007 | US20070117129 Antigen arrays for treatment of bone disease |
| 05/24/2007 | US20070116784 Imatinib combinations for head and neck cancers |
| 05/24/2007 | US20070116725 Live Attenuated Samonella Strains for Producing Monovalent or Multivalent Vaccines |
| 05/24/2007 | US20070116715 Genetically modified cholera toxin (CT-CRM) comprising reduced toxicity and enhanced immunological response for use in preparation of vaccines against parasitic infection |
| 05/24/2007 | US20070116708 Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
| 05/24/2007 | US20070116692 Host cells obtained by introducing and expressing VHL gene in cancer cells or embryonic stem cells |
| 05/24/2007 | US20070116688 Methods of organ regeneration |
| 05/24/2007 | US20070116671 Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| 05/24/2007 | US20070116670 providing a medicament for the therapy of YB-1 positive diseases, in particular of tumor diseases; expressing a gene or gene fragment in a tumor cell |
| 05/24/2007 | US20070116647 Medicinal preparation particularly for the treatment of slipped discs hernias |
| 05/24/2007 | US20070116644 Detectable labeled cobalamin (adenosylcolbalamin) conjugated with peptidesor amino acid residues linked to a chelate compound (ETDA) including a metal radionuclide;antitumor, anticarcinogenic agents; contrast agent for imaging; diagnosis; nontoxic;bioavailability; detectable at low concentrations |
| 05/24/2007 | DE102006053594A1 Verfahren zur Reinigung von Letrozol A process for purifying letrozole |
| 05/24/2007 | DE102006053593A1 Verfahren zur Herstellung von Letrozol Process for the preparation of letrozole |
| 05/24/2007 | DE102006006893B3 New aspoquinolone compounds useful in the preparation of anti-proliferative therapeutics |
| 05/24/2007 | CA2669549A1 Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| 05/24/2007 | CA2630559A1 Modified pore-forming protein toxins and use thereof |
| 05/24/2007 | CA2630349A1 Stabilizing formulations for recombinant viruses |
| 05/24/2007 | CA2630203A1 3,6-dihydro-2-oxo-6h-1,3,4-thiadiazine derivatives |
| 05/24/2007 | CA2630202A1 Substituted 5-phenyl-3,6-dihydro-2-oxo-6h[1,3,4]-thiadiazines |
| 05/24/2007 | CA2630175A1 Pharmaceutical composition for treating or preventing ovarian cancer |
| 05/24/2007 | CA2630079A1 Pyrazolothiazole protein kinase modulators |
| 05/24/2007 | CA2629863A1 Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors |
| 05/24/2007 | CA2629781A1 Aminopyrimidines useful as kinase inhibitors |
| 05/24/2007 | CA2629715A1 Anti-alpha2 integrin antibodies and their uses |
| 05/24/2007 | CA2629714A1 Administration of an mtor inhibitor to treat patients with cancer |
| 05/24/2007 | CA2629638A1 Scutellaria barbata extract for the treatment of cancer |
| 05/24/2007 | CA2629532A1 Method of expanding double negative t cells |
| 05/24/2007 | CA2629468A1 Pyrazolyl urea derivatives useful in the treatment of cancer |
| 05/24/2007 | CA2629455A1 Heteroalkyl linked pyrimidine derivatives |
| 05/24/2007 | CA2629443A1 Oxygen linked pyrimidine derivatives |
| 05/24/2007 | CA2629245A1 Neuroendocrine tumor treatment using mtor inhibitors |
| 05/24/2007 | CA2629095A1 Anti-egfr antibodies |
| 05/24/2007 | CA2628630A1 Compositions of lipoxygenase inhibitors |
| 05/24/2007 | CA2628461A1 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| 05/24/2007 | CA2628455A1 Imidazopyrazines as protein kinase inhibitors |
| 05/24/2007 | CA2628332A1 New method for treating cancer based on the modulation of calcineurin |
| 05/24/2007 | CA2628179A1 Azaindazoles useful as inhibitors of kinases |
| 05/24/2007 | CA2627965A1 Imidazopyrazines as cyclin dependent kinase inhibitors |
| 05/24/2007 | CA2627190A1 Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| 05/23/2007 | EP1788390A1 Screening method |
| 05/23/2007 | EP1788086A1 Death Domain Containing Receptor 5 |
| 05/23/2007 | EP1788085A1 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 05/23/2007 | EP1788083A1 Method of assuming drug sensitivity to cdk4 inhibitor |
| 05/23/2007 | EP1788000A1 Agent for preventing and ameliorating obesity |
| 05/23/2007 | EP1787999A1 Anti-VEGF antibodies |
| 05/23/2007 | EP1787991A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE |
| 05/23/2007 | EP1787986A1 Hydroxamic acid derivative and medicine containing the same as active ingredient |
| 05/23/2007 | EP1787985A1 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom |
| 05/23/2007 | EP1787654A1 A method of inducing a CTL response |
| 05/23/2007 | EP1787653A2 Pharmaceutical composition containing polypeptide fragments of serralysins |
| 05/23/2007 | EP1787645A1 New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway |
| 05/23/2007 | EP1786925A2 Genes and polypeptides relating to breast cancers |
| 05/23/2007 | EP1786905A1 Small interfering rna molecules against ribonucleotide reductase and uses thereof |
| 05/23/2007 | EP1786835A2 Antiangiogenic compounds, pharmaceutical composition containing said compounds and the use thereof |
| 05/23/2007 | EP1786819A1 Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments |
| 05/23/2007 | EP1786818A1 Dihydropteridine derivatives, methods for their preparation and their use as drugs |
| 05/23/2007 | EP1786817A1 Pteridinones used as plk (polo like kinases) inhibitors |
| 05/23/2007 | EP1786803A1 Pyrimidinylpyrazoles as tgf-beta inhibitors |
| 05/23/2007 | EP1786802A1 Pyrimidinylimidazoles as tgf-beta inhibitors |
| 05/23/2007 | EP1786799A1 Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
| 05/23/2007 | EP1786779A1 4-arylazo-3,5-diamino-pyrazole compounds and use thereof |
| 05/23/2007 | EP1786773A1 Isoindolin-1-one derivatives |
| 05/23/2007 | EP1786519A1 Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer |
| 05/23/2007 | EP1786469A2 Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
| 05/23/2007 | EP1786466A2 Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors |
| 05/23/2007 | EP1786456A1 Use of apo2l receptor agonists and nk cells or nk cell activators |
| 05/23/2007 | EP1786452A1 Use of dm43 and its fragments as matrix metalloproteinases inhibitor |
| 05/23/2007 | EP1786448A1 Use of gsk-3 inhibitors for the treatment of prostate cancer |
| 05/23/2007 | EP1786439A2 Methods of activating nkt cells |
| 05/23/2007 | EP1786430A2 Small molecules that replace or agonize p53 function |
| 05/23/2007 | EP1786412A1 Arene ruthenium (ii) compounds and their use in cancer therapy |